Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual modeof action: serotonin reuptake inhibition and 5-HT1A receptor antagonism
Am. Oficialdegui et al., Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual modeof action: serotonin reuptake inhibition and 5-HT1A receptor antagonism, FARMACO, 55(5), 2000, pp. 345-353
It has been suggested that the combination of a selective serotonin reuptak
e inhibitor (SSRI) and a 5-HT1A receptor antagonist may facilitate the onse
t of the SSRIs antidepressant action. Accordingly, we describe the synthesi
s of a series of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives w
ith structural modifications performed in Ar-1, Ar-2 and Z (Z is different
functional groups) to obtain the sought dual activity. Compounds were evalu
ated for in vitro affinity at 5-HT1A receptors and 5-HT transporter. The an
tidepressant-like activity of derivatives with the higher affinity was asse
ssed initially using the forced swimming test (FST). Compound 1 -(2,4-dimet
hylphenyl)-3-[(2-methoxyphenyl)piperazin-1-il]-1-propanone (III.1.a) showed
the best antidepressant-like activity which was further confirmed in the l
earned helplessness test. (C) 2000 Elsevier Science S.A. All rights reserve
d.